Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Prelude Therapeutics Inc entered into Amended and Restated Registration Rights Agreement with the Company and the Purchasers (effective 2023-12-11).
- Action
- entry
- Counterparty
- the Company and the Purchasers
- Effective
- 2023-12-11
Exact text from the filing
the Company and the Purchasers also entered into an Amended and Restated Registration Rights Agreement, dated as of December 11, 2023 (the “ Amended and Restated Registration Rights Agreement ”), providing for the registration for resale of the shares of Common Stock underlying the Pre-Funded Warrants
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Prelude Therapeutics Inc entered into Securities Purchase Agreement with certain institutional accredited investors (effective 2023-12-11).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional accredited investors
- Effective
- 2023-12-11
Exact text from the filing
On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to 7,936,759 shares of the Company’s voting common stock, par value $0.0001 per share (the “ Common Stock ”), at a price of $3.1499 per warrant with an exercise price of $0.0001 per share
View on SEC.gov